These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
482 related articles for article (PubMed ID: 27987627)
1. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627 [TBL] [Abstract][Full Text] [Related]
2. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750 [TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005 [TBL] [Abstract][Full Text] [Related]
4. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416 [No Abstract] [Full Text] [Related]
5. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. Wu B; Shi L JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281 [TBL] [Abstract][Full Text] [Related]
7. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Tarhini A; Benedict A; McDermott D; Rao S; Ambavane A; Gupte-Singh K; Sabater J; Ritchings C; Aponte-Ribero V; Regan MM; Atkins M Immunotherapy; 2018 Oct; 10(14):1241-1252. PubMed ID: 30175642 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037 [No Abstract] [Full Text] [Related]
10. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122 [TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada. Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880 [TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365 [TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal. Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438 [TBL] [Abstract][Full Text] [Related]
17. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab in previously untreated melanoma without BRAF mutation. Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552 [TBL] [Abstract][Full Text] [Related]
19. Nivolumab: A Review in Advanced Melanoma. Scott LJ Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912 [TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]